18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
19:14 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
00:27 , Nov 15, 2017 |  BC Extra  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing , neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are...